Purinergic Signaling in Neurodegeneration

Purinergic Signaling in Neurodegeneration

Introduction

Purinergic signaling refers to the signaling pathways mediated by purine nucleotides and nucleosides (ATP, ADP, adenosine) through activation of purinergic receptors (P1, P2X, P2Y). This ancient signaling system plays crucial roles in neural development, synaptic transmission, glial function, and neuroinflammation. Dysregulation of purinergic signaling contributes to neurodegenerative processes through multiple mechanisms [@calovi2021].

Key aspects include:

• ATP release: Activity-dependent ATP release from neurons and astrocytes
• Receptor activation: P2X (ionotropic) and P2Y (metabotropic) receptors mediate fast and modulatory signaling
• Adenosine signaling: A1, A2A, A2B, A3 receptors modulate neuronal excitability and inflammation
• Neuroinflammation: P2X7 and A2A receptors regulate microglial activation and cytokine release

Purinergic Receptor Families

P2X Receptors (Ionotropic)

P2X receptors are ligand-gated ion channels activated by extracellular ATP. Seven subtypes (P2X1-P2X7) form trimeric assemblies that permit cation influx (Na+, Ca2+, K+). In the CNS, the most relevant are [@recourt2020]:

| Receptor | Primary CNS Expression | Key Functions |
|----------|----------------------|---------------|
| P2X4 | Microglia, neurons | Microglial activation, BDNF release, neuropathic pain |
| P2X7 | Microglia, neurons | Nociception, neurotransmission, inflammasome activation |
| P2X1 | Smooth muscle, platelets | Vasoconstriction, platelet aggregation |

Purinergic Signaling in Neurodegeneration

Introduction

Purinergic signaling refers to the signaling pathways mediated by purine nucleotides and nucleosides (ATP, ADP, adenosine) through activation of purinergic receptors (P1, P2X, P2Y). This ancient signaling system plays crucial roles in neural development, synaptic transmission, glial function, and neuroinflammation. Dysregulation of purinergic signaling contributes to neurodegenerative processes through multiple mechanisms [@calovi2021].

Key aspects include:

• ATP release: Activity-dependent ATP release from neurons and astrocytes
• Receptor activation: P2X (ionotropic) and P2Y (metabotropic) receptors mediate fast and modulatory signaling
• Adenosine signaling: A1, A2A, A2B, A3 receptors modulate neuronal excitability and inflammation
• Neuroinflammation: P2X7 and A2A receptors regulate microglial activation and cytokine release

Purinergic Receptor Families

P2X Receptors (Ionotropic)

P2X receptors are ligand-gated ion channels activated by extracellular ATP. Seven subtypes (P2X1-P2X7) form trimeric assemblies that permit cation influx (Na+, Ca2+, K+). In the CNS, the most relevant are [@recourt2020]:

| Receptor | Primary CNS Expression | Key Functions |
|----------|----------------------|---------------|
| P2X4 | Microglia, neurons | Microglial activation, BDNF release, neuropathic pain |
| P2X7 | Microglia, neurons | Nociception, neurotransmission, inflammasome activation |
| P2X1 | Smooth muscle, platelets | Vasoconstriction, platelet aggregation |

P2Y Receptors (Metabotropic)

P2Y receptors are G-protein-coupled receptors activated by ATP, ADP, UTP, or UDP. Eight subtypes signal through Gq/11, Gi/o, or Gs pathways [@ribeiro2021]:

| Receptor | Primary CNS Expression | Key Functions |
|----------|----------------------|---------------|
| P2Y1 | Astrocytes, neurons | Calcium waves, glutamate release |
| P2Y6 | Microglia | UDP-activated phagocytosis |
| P2Y12 | Homeostatic microglia | Chemotaxis, surveillance, synaptic monitoring |
| P2Y13 | Microglia, oligodendrocytes | Process extension, ADP sensing |

P1 (Adenosine) Receptors

Adenosine receptors are G-protein-coupled receptors activated by adenosine, the breakdown product of ATP via ectonucleotidases (CD39 and CD73):

| Receptor | Coupling | Key Functions |
|----------|----------|---------------|
| A1 | Gi/o (inhibitory) | Neuroprotection, presynaptic inhibition, anti-inflammatory |
| A2A | Gs (excitatory) | Pro-inflammatory microglial activation, synaptic modulation |
| A2B | Gs | Astrocyte activation, vascular regulation |
| A3 | Gi/o | Microglial process motility, mixed effects |

ATP as a Danger Signal in Neurodegeneration

ATP Release Mechanisms

In the healthy brain, ATP is released in a controlled manner from synaptic vesicles and through pannexin channels during normal neurotransmission. In neurodegenerative diseases, pathological ATP release occurs through multiple mechanisms [@illes2024]:

Ectonucleotidase Cascade

Extracellular ATP is rapidly metabolized by ectonucleotidases:

ATP - (CD39/NTPDase1) -> ADP - (CD39) -> AMP - (CD73/ecto-5'-nucleotidase) -> Adenosine - (adenosine deaminase) -> Inosine

This cascade determines the balance between ATP-driven inflammation (via P2 receptors) and adenosine-mediated neuroprotection (via A1 receptors). In neurodegeneration, changes in ectonucleotidase expression alter this balance, often favoring sustained ATP signaling.

The P2X7 Receptor: Central Hub of Neuroinflammation

Unique Properties of P2X7

The P2X7 receptor (P2X7R) has several properties that distinguish it from other P2X family members and make it particularly important in neurodegeneration [@deussing2022]:

• Low ATP affinity: Requires high (>100 uM) ATP concentrations for activation, meaning it is primarily activated under pathological conditions
• Pore formation: Sustained activation opens a large non-selective pore (permeant to molecules up to ~900 Da), enabling release of pro-inflammatory mediators
• NLRP3 inflammasome activation: P2X7R is the canonical trigger of NLRP3 inflammasome assembly, leading to caspase-1 activation and IL-1beta maturation and release
• Absence of desensitization: Unlike other P2X receptors, P2X7R does not desensitize during sustained stimulation, enabling persistent inflammatory signaling

P2X7R and the NLRP3 Inflammasome

The P2X7R-NLRP3 inflammasome axis represents a critical link between purinergic signaling and neuroinflammation [@bhatt2019]:

P2X7R in Alzheimer's Disease

In AD, amyloid-beta aggregates activate P2X7R on perivascular microglia, driving chronic IL-1beta release and creating a self-amplifying neuroinflammatory cycle [@illes2024]. Key findings:

• P2X7R expression is upregulated in AD patient microglia and brain tissue
• A-beta-P2X7R interaction triggers NLRP3 inflammasome activation
• P2X7R blockade reduces neuroinflammation and improves cognition in animal models
• P2X7R genetic variants may modify AD risk

P2X7R in Parkinson's Disease

• Extracellular alpha-synuclein activates microglial P2X7R, inducing oxidative stress and NLRP3-mediated inflammation
• P2X7R activation contributes to dopaminergic neuron loss in the substantia nigra
• P2X7R-pannexin-1 interaction mediates alpha-synuclein-induced ATP release
• P2X7R expression is elevated in PD substantia nigra and striatum

P2X7R in Amyotrophic Lateral Sclerosis

• P2X7R is upregulated in SOD1 mouse motor neurons and glia
• P2X7R activation contributes to excitotoxicity and motor neuron death
• P2X7R blockade delays disease progression in SOD1 models
• P2X7R polymorphisms may influence ALS susceptibility

Adenosine A1 Receptors: Neuroprotection

The adenosine A1 receptor provides constitutive neuroprotection through:

• Presynaptic inhibition of glutamate release, opposing excitotoxicity
• Reduction of neuronal metabolic demand
• Anti-inflammatory effects on microglia
• Promotion of sleep and neural restoration

Adenosine A2A Receptors: Dual Role

A2A receptors have a complex role in neurodegeneration:

• Pro-inflammatory: A2A activation on microglia promotes pro-inflammatory phenotype
• Synaptic modulation: A2A receptors modulate dopamine signaling and synaptic plasticity
• Clinical use: A2A antagonists (istradefylline) are FDA-approved for PD as adjunctive therapy

Istradefylline (Nourianz)

• Adenosine A2A receptor antagonist, FDA-approved (2020) as adjunctive treatment for OFF episodes in PD
• Mechanism: Blocks adenosine A2A receptors in the striatum, disinhibiting the direct motor pathway
• May have disease-modifying potential through anti-neuroinflammatory effects
• Dose: 20 mg once daily, can be taken with or without levodopa/carbidopa

Purinergic Signaling in Astrocytes

Astrocytes are major participants in purinergic signaling:

• Calcium waves: ATP released from astrocytes activates P2Y1 receptors on neighboring astrocytes, propagating calcium waves across astrocyte networks — a form of gliotransmission that can modulate neuronal activity over large distances
• Glutamate release: Astrocytic P2X7R and P2Y1 activation triggers glutamate release, potentially contributing to excitotoxicity
• Reactive astrogliosis: P2Y1 and P2X7 signaling drives astrocyte reactivity in neurodegeneration
• Blood-brain barrier regulation: Astrocytic purinergic signaling modulates BBB permeability

Therapeutic Targeting of Purinergic Signaling

P2X7 Receptor Antagonists

Multiple P2X7R antagonists are being developed for neurological indications [@recourt2020]:

| Compound | Company | Development Status | Notes |
|----------|---------|-------------------|-------|
| JNJ-54175446 | Janssen | Phase 1 completed | Brain-penetrant, showed target engagement in hippocampus |
| CE-224,535 | Pfizer | Phase 2 RA (ceased) | Anti-inflammatory |
| AZD9056 | AstraZeneca | Phase 2 (ceased) | Inflammatory conditions |
| GSK1482160 | GSK | Preclinical | PET ligand and therapeutic candidate |

Adenosine A2A Receptor Antagonists

| Compound | Status | Indication |
|----------|--------|------------|
| Istradefylline (Nourianz) | FDA-approved 2020 | PD OFF episodes |
| Preladenant | Phase 3 (ceased) | PD |
| Tozadenant | Phase 3 (ceased) | PD |
| Caffeine | Epidemiologic | Neuroprotective (epidemiological data) |

CD39/CD73 Modulation

Targeting ectonucleotidases to shift the ATP/adenosine balance represents a newer therapeutic approach. Enhancing CD39 activity could reduce pro-inflammatory ATP levels while increasing neuroprotective adenosine.

P2Y12 Agonists

Strategies to maintain or restore microglial P2Y12 expression in disease states could help preserve homeostatic surveillance and neuroprotection.

Purinergic Signaling as a Biomarker

Several purinergic components are being investigated as biomarkers:

• CSF ATP levels: Elevated in AD and PD patients, correlating with disease severity
• P2X7R PET ligands: Radioligands like 11C-JNJ-54173717 enable in vivo imaging of P2X7R expression, providing a biomarker of neuroinflammation
• Plasma adenosine: Altered adenosine metabolism may serve as a peripheral biomarker
• CD39/CD73 expression: Changes in ectonucleotidase activity on circulating immune cells may reflect CNS purinergic dysfunction

See Also

• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [NLRP3 Inflammasome in Neurodegeneration](/mechanisms/nlrp3-inflammasome)
• [Microglial Activation in AD/PD](/mechanisms/microglial-activation)
• [Astrocyte Reactivity](/mechanisms/astrocyte-reactivity)
• [Excitotoxicity in Neurodegeneration](/mechanisms/excitotoxicity)

Confidence Assessment

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 10 primary references |
| Replication | Multiple studies replicated across AD, PD, ALS |
| Effect Sizes | Moderate |
| Contradicting Evidence | Some conflicting data on A2A antagonism timing |
| Mechanistic Completeness | 50% |

Overall Confidence: 45%

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
• [Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
• [Gap Junction Hemichannel Modulation for Controlled Mitochondrial Exchange](/hypothesis/h-9adb5c9e) — <span style="color:#ffd54f;font-weight:600">0.50</span> · Target: PANX1